198 related articles for article (PubMed ID: 2469721)
1. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
[TBL] [Abstract][Full Text] [Related]
2. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
Hart MK; Palker TJ; Matthews TJ; Langlois AJ; Lerche NW; Martin ME; Scearce RM; McDanal C; Bolognesi DP; Haynes BF
J Immunol; 1990 Oct; 145(8):2677-85. PubMed ID: 1698859
[TBL] [Abstract][Full Text] [Related]
3. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
4. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
[TBL] [Abstract][Full Text] [Related]
5. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.
Krohn K; Robey WG; Putney S; Arthur L; Nara P; Fischinger P; Gallo RC; Wong-Staal F; Ranki A
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4994-8. PubMed ID: 2440037
[TBL] [Abstract][Full Text] [Related]
6. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
8. Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.
Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
Haematol Blood Transfus; 1987; 31():414-22. PubMed ID: 2832276
[TBL] [Abstract][Full Text] [Related]
9. C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.
Devash Y; Matthews TJ; Drummond JE; Javaherian K; Waters DJ; Arthur LO; Blattner WA; Rusche JR
AIDS Res Hum Retroviruses; 1990 Mar; 6(3):307-16. PubMed ID: 2340200
[TBL] [Abstract][Full Text] [Related]
10. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
Matsushita S; Robert-Guroff M; Rusche J; Koito A; Hattori T; Hoshino H; Javaherian K; Takatsuki K; Putney S
J Virol; 1988 Jun; 62(6):2107-14. PubMed ID: 2452899
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
Scott CF; Silver S; Profy AT; Putney SD; Langlois A; Weinhold K; Robinson JE
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8597-601. PubMed ID: 1700435
[TBL] [Abstract][Full Text] [Related]
13. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
[TBL] [Abstract][Full Text] [Related]
14. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
Cease KB; Margalit H; Cornette JL; Putney SD; Robey WG; Ouyang C; Streicher HZ; Fischinger PJ; Gallo RC; DeLisi C
Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4249-53. PubMed ID: 2438696
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.
Durda PJ; Bacheler L; Clapham P; Jenoski AM; Leece B; Matthews TJ; McKnight A; Pomerantz R; Rayner M; Weinhold KJ
AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1115-23. PubMed ID: 1702301
[TBL] [Abstract][Full Text] [Related]
16. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
Nara PL; Robey WG; Pyle SW; Hatch WC; Dunlop NM; Bess JW; Kelliher JC; Arthur LO; Fischinger PJ
J Virol; 1988 Aug; 62(8):2622-8. PubMed ID: 3392769
[TBL] [Abstract][Full Text] [Related]
17. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
[TBL] [Abstract][Full Text] [Related]
18. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
Neurath AR; Strick N
Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
[TBL] [Abstract][Full Text] [Related]
19. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
Fung MS; Sun CR; Gordon WL; Liou RS; Chang TW; Sun WN; Daar ES; Ho DD
J Virol; 1992 Feb; 66(2):848-56. PubMed ID: 1370558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
